SEATTLE, April 18, 2017 /PRNewswire/ — LumiThera® Inc., a clinical stage medical device company focused on delivering non-invasive photobiomodulation (PBM) therapies for ocular disorders and disease, today announced it has been awarded the prestigious “MOST INNOVATIVE AND PROMISING MEDTECH & E-HEALTH COMPANY” during Biovision 2017 in Lyon, France.
Biovision is a high-level investor event connecting industrial partners, financial investors and the best medical technology, biotechnology, and e-health start-up and mid-size companies (www.biovision.org). The most promising companies in each category are awarded based upon key criteria such as societal benefit, market attractiveness, innovative approach, competitive position, team structure and attractiveness for investment.
This is the second year that LumiThera received the top award in its respective categories. In 2016, LumiThera was the winner in the Catalyzer category and this year it won first place in the Investor category on a unanimous vote. Selected from a pool of applicants by a special Biovision committee, companies with the greatest potential to offer innovative health solutions were invited to present during the Biovision forum in front of a jury comprised of leading European private and corporate investors in the life sciences.
“We are delighted that Biovision has recognized the scientific, clinical and product development progress LumiThera made over the last year in advancing towards the commercial introduction of our innovative technology for treating dry age related macular degeneration (AMD), one of the leading causes of blindness in the world,” said Clark Tedford, Ph.D., Chief Executive Officer. “We are honored to have received this second award as we prepare to bring this important therapy to the millions of patients suffering from dry AMD who have no other treatment alternatives.”
About Age Related Macular Degeneration (AMD)
Age-related macular degeneration (AMD) accounts for 8.7% of all blindness worldwide and is the most common cause of blindness according to the World Health Organization. Disease prevalence is likely to increase due to population aging. Approximately, 85-90% of AMD is the “dry” form of the disease. The emotional and socioeconomic impact of AMD is large because vision impairment caused by the disease, which primarily affects central (straight-on) rather than peripheral (side) vision can severely impact daily activities such as reading and driving.
About LumiThera Inc.
LumiThera, Inc. is a developmental-stage medical device company initially focused on treating patients affected by dry age-related macular degeneration. The Company’s expertise is in the application of photobiomodulation (“PBM”), using non-invasive light emitting diodes (“LED”) for acute and chronic ocular diseases and disorders. The Company is developing an ophthalmic LED office-based instrument to be used in multiple ocular conditions or disorders as non-invasive medical treatments.
Two clinical studies have demonstrated clinical and pathological benefits of PBM in treating subjects with dry AMD. The recent TORPA II clinical trial results demonstrating improvements in clinical outcomes of vision and reduction of pathological “drusen” following imaging analysis were published in December 2016 in ACTA Ophthalmologica, a top peer-reviewed Ophthalmology journal. The company is currently testing their LT-300 device in a thirty subject dry AMD study partially supported by the National Eye Institute. This randomized, sham controlled, clinical study is fully enrolled and interim outcomes are expected in 2017.
The LT-300 is currently in clinical trials and is not CE Marked nor FDA 510K Cleared.
2017 LumiThera Inc., All rights reserved.
Visit the Company’s website at www.lumithera.com
SOURCE LumiThera Inc.
下一篇：LumiThera Closes Series B Round of Financing
- 友情链接：
- 百度
